The Brief Review on RA

Shubham Kishor Wackchaure, Mr.Dnyaneshwar S.Vyavhare, Dr.Megha T.Salve.
Shivajirao Pawar College of pharmacy, Pachegaon-Newasa,414602

Abstract: The field of regulatory affairs (RA), which includes the scientific and legal facets of drug development, is vital to the pharmaceutical, medical device, and biotechnology industries. It guarantees commercialization and assists businesses in avoiding problems. Geopolitical changes, the green economy, and COVID-19 are some of the issues that RA encounters, which affects novel treatments and their function. Regulatory Drugs Pharmaceutical firms ' Department of Regulatory Affairs (DRA) is an essential division that offers operational, tactical, and strategic support to accelerate the creation and distribution of safe and effective pharmaceutical, veterinary, medical device, pesticide, and agrochemical products cosmetics and medical supplies. One of the sectors in India that is expanding the quickest is the pharmaceutical sector, which has a above 13% compound annual growth rate during the previous five years.

Opportunities to speed up medication research and regulatory approval processes are provided by the European Medicines Agency and the US Food and medication Administration. Pharmaceutical disasters of the 1950s, such as those involving thalidomide, vaccines, and sulfanilamide elixir, resulted in stricter regulations and increased requirements for Good Manufacturing. practices and heightened regulatory oversight in Europe, India, and the United States. Registration of drugs is controlled by development and marketing, but commercialization can be difficult. Regulatory agencies deal with secondary, executive, and nonsupervisory laws. both regulation and law. Independent regulatory bodies are established to handle complexity, political meddling, and rapid application. carrying out inquiries, audits, and putting limitations in place. In pharmaceutical research and development, the drug regulatory affairs (DRA) specialist plays a critical role in guaranteeing regulatory compliance with the Food and Drug Act and TPP Guidelines/Policies.

They must have outstanding writing and communication abilities, receive clearance from Health Canada's Therapeutic Products Program, and can successfully bargain for favorable labeling. As a full-time or part-time employee, the RA is essential to many systems.The scale of the design, the perceived difficulty of the circumstances, and the available resources all affect how many RAs there are and their skill levels. resources. RAs should be seen as essential contributors, needing a special combination of expertise, practical experience, and the capacity to decipher and fulfill the intentions of visitors, drug users, and the operation. Throughout the whole medication development process, from research to commercialization, the regulatory department is in charge of making sure manufacturers adhere to international legal and regulatory regulations. They advise on legal and scientific restrictions and monitor current legislation across the world. For regulatory submissions, regulatory affairs specialists gather, interpret, and recognize scientific and clinical data. Additionally, they offer technical and strategic guidance to functional domains such as clinical research, commercial marketing, and medical affairs. Because yearly reports must be submitted to the FDA or other regulatory organizations, they also guarantee proper records and documentation.

Keywords: Introduction, History, USFDA, CDSCO, TGA, CTD, eCTD.

1) INTRODUCTION

The field of regulatory affairs (RA) encompasses both the scientific and legal facets of drug development and is found in the pharmaceutical, medical device, and biotechnology sectors. It assists businesses in avoiding issues brought on by improperly maintained records, faulty data presentation, or improper scientific thinking. Additionally, it is essential for medication development in order to commercialize into the target market.[1]

The regulatory standards for marketing authorization of medicinal medicines are the focus of the regulatory affairs area. Numerous factors are at play in this field, including the emergence of the green economy, changes in geopolitics, and the COVID-19 outbreak. This piece will go over the several developments that are influencing the creation of novel treatments and how the regulatory affairs function is affected by these tendencies competent.[2,3]

Drug Regulatory Affairs:

An essential department within a pharmaceutical company is Drug Regulatory Affairs (DRA), which offers operational, tactical, and strategic guidance and support for working within regulations to speed up the development and delivery of safe and effective pharmaceuticals, veterinary medications, medical

devices, pesticides, agrochemicals, cosmetics, complementary medicines, and healthcare products to people worldwide.[4]

RA specialists work in government agencies, healthcare facilities, academic research, and the pharmaceutical sector. The Indian One of the sectors with the quickest growth is the pharmaceutical business. Indian industries, which are growing at a compound annual growth rate ofmore than 13% during the last five years and is anticipated to expand at a greater pace for the next ten years. The market for clinical trials is valued at USD 52 billion globally, and India is anticipated to increase to 1.5–2 billion USD. There is a significant need for clinical study with competent RA staff, and the US Food and the European Medicines Agency and the Drug Administration provide chances to accelerate the development of new drugs and timeframes for regulatory clearance. Professionals that take pride in their ability to improve people's health and quality of life oversee pharmaceutical medication regulations.[5]

A pharmaceutical company's Drug Regulatory Affairs (DRA) department is crucial because it offers operational, tactical, and strategic guidance and assistance in adhering to regulations. With a clinical research market valued at USD 52 billion, the Indian pharmaceutical industry is one of the fastest-growing in the nation. The European Medicines Agency and the US Food and medication Administration might expedite the medication research and regulatory approval processes.[6]

Origin/History of Regulatory Affairs:

Laws pertaining to the efficacy, safety, and quality of pharmaceutical goods were significantly expanded as a result of several tragedies that occurred in the 1950s, such as the thalidomide, immunization, and sulfanilamide elixir incidents. This has also resulted in stricter guidelines for marketing authorization (MA) and good manufacturing practices (GMPs). Let's examine what happened in India, Europe, and the United States.[7]

Historical Overview of Pharmaceutical Industry and Drug Regulatory Affairs:

A) United States of America (USA):

Glycerin was initially produced on a considerable scale in the early eighteenth century, along with the establishment of chemical production facilities. The contemporary pharmaceutical business in the United States had its roots in the Mexican-American War. Custom Laboratories were founded by the Import Drugs Act of 1848, which also acknowledged the US Pharmacopoeia as an official compendium. Due to several disasters that occurred all over the world at the beginning of the nineteenth century, new laws pertaining to the regulation of medications began to take effect. In 1901, tetanus-causing bacteria tainted the diphtheria antitoxin created by the City Health Department of St. Louis, killing 14 children and caused nine additional fatalities in Camden, New Jersey.[8]

The vaccination catastrophe led to the Biologics Control Act of 1902, which required genetic product manufacture and distribution licenses. Drug components and contents must be labeled, according to the Food and Drugs Act of 1906. The Federal Food and Drugs Act of 1906 served as the foundation for the Food and Drug Administration's (FDA) ultimate establishment. The Food, Drug, and Cosmetic Act of 1938 was a result of the 1938 Sulfanilamide Elixir disaster, which raised questions over the safety of pharmaceutical goods. This law demanded evidence for a scientific safety evaluation and required pre-marketing approval for all new medications.[9]

(B)European union (EU):

Keeping harmful products off the market is the main objective of healthcare regulations in European countries. Quality, Safety, and Efficacy were the only factors that led to the highly developed state of affairs and well defined legal framework of the pharmaceutical sector.[10]

Economic issues:

The first health insurance program was created in the early 20th century. Price transparency has resulted from the cost of medications being transferred from the customer to the public and commercial health insurance systems.[5]

REGULATORY AUTHORITY IN DIFFERENT COUNTRIES

USA	Food and Drug Administration (FDA)
UK	Medicines and Healthcare Products Regulatory Agency (MHRA)
Australia	Therapeutic Goods Administration (TGA)
India	Central Drug Standard Control Organization (CDSCO)

Canada	Health Canada
Europe	European Medicines Agency (EMEA)

USA:

The United States Department of Health and Human Services is home to the Food and Drug Administration (FDA or U.S.FDA), a government department. The United States Congress gave the FDA the authority to implement the Federal Food, Drug, and Cosmetic Act. Additionally, the U.S. FDA implements additional laws, including the Public Health Service Act and related rules, many of They have nothing to do with diet or medications. White House is home to the U.S. FDA's headquarters. Land of Oak Mary. Additionally, the organization has 13 laboratories and 223 field offices spread aroundthe 50 states. China, India, Chile, Belgium, and the United Kingdom were among the nations where the U.S. FDA began to build offices in 2008.[11]

USFDA:

The U.S. Department of Health and Human Services, one of the federal executive departments of the United States, houses the U.S. Food and Drug Administration (FDA or USFDA), a regulatory body. U.S. headquarters are located in Silver Spring, Maryland. formed on June 24, 1938.In order to safeguard and advance public health, the USFDA regulates and oversees the safety of food, tobacco products, dietary supplements, pharmaceutical drugs (medications), both prescription and over-the-counter, vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation emitting devices (ERED), veterinary products, and cosmetics.[12]

US-FDA Guidelines :

Part of title21CFR

Part of 58: Good laboratory practice for nonclinical laboratory studies.

Part of 101:-Food labelling.

Part of 110:- Current good manufacturing practice in manufacturing, packing, or holding human food.

Part of 201:- Labelling.

Part of 312:- Investigational new drug application.

Part Of 314:-Applications for FDA approval to market new drug.

Part of 328:- Over - the – counter drug products intended for oralingestion that contain alcohol.

Part of 331:- Antacid products for over-the-counter (OTC) human use. Part of 341:-Cold, cough, allergy, bronchodilator, and antiasthmatic drug products forover the-counter human used. Part of 600:- Biological products: general.

Part of 820:- Quality system regulation.

Part of 892:-Radiology devices.

Part of 1392:-Registration of manufacturers, distributors, importers and exporter so flist.[13]

FUNCTIONS:

1.To offer suggestions for improving uniformity in the implementation and interpretation of technical specifications and guidelines for pharmaceutical product registration and registration maintenance;

2. to keep a platform for the pharmaceutical sector and regulatory bodies to have fruitful discussions on scientific matters regarding the harmonization of technical specifications for pharmaceutical goods;

3. to help safeguard public health from an international standpoint in the benefit of patients;

4. to keep an eye on and update standardized technical specifications that will increase the adoption of research and development data by both parties;

5. to prevent disparate future needs by harmonizing a few issues that are required due to advancements in therapy and the creation of new technology for the manufacturing of pharmaceuticals;

6. to make it easier for new or enhanced technological research and development methods to be used, updating or replacing existing ones;

7. To promote the proper application and integration of common standards by means of information sharing, training coordination, and the distribution of standardized guidelines and their application;

8. And to develop policy for the ICH Medical Dictionary for Regulatory Activities Terminology (Med DRA) whilst ensuring the scientific and technical maintenance, development and dissemination of Med DRA as a standardised dictionary which facilitates hesaring of regulatory information internationally for medicinal products used by humans.[14]

INDIA:

The Indian parliament established the Drug and Cosmetic Act 1940 and Rules 1945 to control the import, production, distribution, and retailing of pharmaceuticals and cosmetics. The establishment of the Central Drugs Standard Control Organization (CDSCO) and the Drugs Controller General's (DCGI) office followed. Schedule Y was introduced to the Drug and Cosmetics Rules 1945 by the Indian government in 1988. The standards and procedures for clinical trials are outlined in Schedule Y, which was updated in 2005 to align with globally recognized practices. In order to produce or import a novel medicine in India, a business must apply for approval from the licensing body (DCGI) by submitting Form 44 together with the information specified in Schedule Y of the Drugs and Cosmetics Act 1940 and Rules 1945.[15]
It must carry out clinical trials in compliance with the guidelines listed in Schedule Y and submit the results of those clinical trials in the manner prescribed in order to demonstrate its effectiveness and safety in the Indian population.[16,17]

The Central Drugs Standard Control Organisation (CDSCO):

The National Regulatory Authority (NRA) of India is the Central Drugs Standard Control Organization (CDSCO), which is a division of the Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India. In addition to its headquarters at FDA Bhawan, Kotla Road, New Delhi 110002, it maintains thirteen zonal offices and four sub-zonal offices. There are seven laboratories and a port office located around the nation. A number of duties pertaining to the regulation of pharmaceuticals and cosmetics have been delegated to central and state regulators by the pharmaceuticals & Cosmetics Act of 1940 and its regulations from 1945. It envisions consistent application of the Act's and its implementing regulations to ensure patients' safety, rights, and well-being by controlling drugs and cosmetics.[18]

In order to guarantee the safety, effectiveness, and quality of the medical products produced, imported, and disseminated inside the nation, CDSCO is continuously striving to promote transparency, accountability, and standardization in its services. In accordance with the Drugs and Cosmetics Act, CDSCO is in charge of drug approval, conduct conducting clinical trials, establishing guidelines for medications, and managing the quality of imported Drugs throughout the nation and the coordination of State Drug Control Organizations' operations by offering professional advice in an effort to create consistency in the cement of the Cosmetics and Drugs Act. Additionally, CDSCO and state regulators work together to in charge of granting licenses for specific specialized categories of vital drugs, including blood and its derivatives,I.V FLUIDS, Vaccines, Sera.[19]

Function and duties:

1. examining the bills of entry to make sure the imported medications adhere to the provisions of the Narcotic Drugs and Psychotropic Substances Act (NDPS) & Rules thereunder, the Drugs and Cosmetic Act & Rules thereunder, the Drugs and Magic Remedies (Objectionable Advertisements) Act and Rules thereunder, and any other currently enacted laws.
2. to maintain control under the Narcotic Drugs and Psychotropic Substances Act & Rules and verify that export shipping invoices comply with the Drugs & Cosmetics Act.
3. According to the Narcotic Drugs and Psychotropic Substances Act & Rules, a certificate issued by the Narcotics Commissioner must be verified for import/export, and the Deputy Drugs Controller (India) of the corresponding Zones must provide the Drugs Controller General (India) with the relevant information.
4. to guarantee that no new drugs are brought into the nation until approved by the Drugs Licensing Authority in accordance with Rules (Rules 122 A & 30-AA).
5. To guarantee that modest amounts of imported medications for clinical trials, testing, examination, and analysis, or personal use are appropriately covered by test licenses (11 or 11-A) or permit licenses (12 B), as applicable
6. The Deputy Drugs Controller (India) of the relevant zones and other agencies as needed receive monthly statistics on imports and exports of pharmaceutical drugs, cosmetics, and medical equipment. (7) Working together with the Customs CommissionerThe pertinent provisions of the DGFT and Customs Act should be well understood by the port officers.
7. Raw material imports under Advance Licenses/100% EOU instances need to be matched with the relevant State Drugs Controller

for a proper post-import inspection, with a copy indicated to the Zone's DDC(I).
8. Provide the necessary information to trade members.
9. Quarterly and annual reports are prepared and sent.
10. Coordination with the customs and other investigating agencies for the matters of violation of import/export under intimation to the DDC (I) of the concerned zone.
11. to inspect unclaimed or confiscated goods after customs refers it and provide an opinion in accordance with established protocol.
12. If any pharmaceuticals or cosmetics are of substandard quality or are suspicious, they should be reported directly to all port offices, with a copy sent to the Deputy pharmaceuticals Controller of the relevant area.

Indian Regulations & Guidelines:

1.CDSCO Central Drugs Standard Control Organization (CDSCO), Ministry of Health& Family Welfare, Government of India provides general information about drug regulatory requirements in India.

2. NPPA Drugs (Price Control) Order 1995 and other orders enforced by National Pharmaceutical Pricing Authority (NPPA), Government of India. View the list of drug sunder price control here…..

3. D & C Act, 1940 The Drugs & Cosmetics Act, 1940 regulates the import, manufacture, distribution and sale of drugs in India.

4. Schedule M Schedule of the D & C Act specifies the general and specific requirements for factory premises and materials, plant and equipment and minimum recommended areas for basic installation for certain categories of drugs.

5. Schedule T Schedule T of the D & C Act prescribes GMP specifications for manufacture of Ayurvedic, Siddha and Unani medicines.

6. Schedule Y The clinical trials legislative requirements are guided by specifications of Schedule Y of The D & C Act.

7. G C P guidelines The Ministry of Health, along with Drugs Controller General of India (DCGI) and Indian Council for Medical Research (ICMR) has come out with draft guide lines for research in human subjects. These GCP guidelines are essentially based on Declaration of Helsinki, WHO guidelines and ICH requirements for good clinical practice.

8. The Pharmacy Act, 1948 The Pharmacy Act, 1948 is meant to regulate the profession of Pharmacy in India.

9. The Drugs and Magic Remedies (Objectionable Advertisement) Act, 1954 The Drugs and Magic Remedies (Objectionable Advertisement) Act, 1954 provides to control the advertisements regarding drugs; it prohibits the advertising of remedies alleged to possess magic qualities.

10. The Narcotic Drugs and Psychotropic Substances Act, 1985 The Narcotic Drugs and Psychotropic Substances Act, 1985 is an act concerned with control and regulation of operations relating to Narcotic Drugs and Psychotropic Substances.[20]

Australia:

The Australian Government Department of Health's Health Products Regulation Group (HPRG), which was founded in 1989, includes the Therapeutic Goods Administration (TGA). The TGA is in charge of the timely availability, efficacy, safety, and quality of medications and medical equipment in Australia through the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations. TGA performs a variety of tasks, including the examination of prescription drugs. In addition, nonprescription medications, medical equipment, and vitamin, nutritional, and herbal items are all governed by the TGA. The Australian Drug Evaluation Committee (ADEC) is the name given to new chemical entities and applications that need expert advice. The TGA ultimately decides whether to register a medication for use in Australia; the ADEC can only offer suggestions. In addition, TGA is in charge of medical equipment, over-the-counter drugs, and alternative pharmaceuticals. In Australia, regulating drugs is a complicated and resource-intensive procedure.[21] TGA is responsible for the efficacy, safety, and quality of medications that are sold in Australia. Accepting a balance between efficacy and safety is part of this accountability. Since there is no such thing as a completely safe medication, the right procedure must assess each drug's risk/benefit ratio. This necessitates a thorough analysis of the information provided by the business supporting an application. When a marketing application is submitted or an Australian clinical study is being planned, the TGA may become aware of a medication. In clinical trials, the sponsoring

corporation either notifies the TGA (CT scheme) that the experiment has been approved by an Institutional Ethics Committee (IEC) or submits preliminary results for examination to the TGA (CTX scheme).[22]

Therapeutic Goods Administration (TGA):

The TGA is in charge of carrying out monitoring and evaluation tasks to guarantee that the therapeutic products that are offered in Australia meet appropriate criteria. Founded on February 15, 1991. The governing body for therapeutic products in Australia is the Therapeutic products Administration (TGA). In order to guarantee that the Australian populace has access to therapeutic advancements in a timely manner, they conduct a series of evaluation and monitoring actions to guarantee that the therapeutic products offered in Australia are of an acceptable grade. TGA controls the quality, availability, and promotion of pharmaceuticals, medical equipment, and other medical products.

Devices, blood products, and the majority of other therapeutic items must be approved by the Therapeutic Goods Authority (TGA) and listed in the Australian Register of Therapeutic Goods. These items must also be used in the administration of medication, have a therapeutic effect, or be covered by the Therapeutic Goods Act 1989, the Therapeutic Goods Regulations 1990, or a ministerial order. In addition, the TGA has seven specialized statutory committees that it can consult for help with technical or scientific matters. In addition, there are four more committees that provide advice on the Therapeutic Goods Advertising Code, industry consultation issues, and yearly influenza vaccinations.[23]

Objective of TGA:

1. To establish a national framework for therapeutic products regulation in Australia in order to guarantee the effectiveness, safety, and quality of medications as well as the performance, safety, and quality of medical devices.
2. In essence, before therapeutic products may be delivered in Australia, they must be listed on the Australian Register of Therapeutic products (ARTG).

Role of the TGA:

1. The registered product's pre-market assessment and approval before going on sale in Australia.
2. The creation, upkeep, and oversight of the medication listing systems.
3. Manufacturer licensing in compliance with global GMP requirements.

TGA structure:

The TGA' s offices are grouped into following core groups

1. TGA Executives.
2. Market Authorization Group (MAG).
3. Monitoring and Compliance Group (MCG).
4. Regulatory Support Group.
5. Office of Regulatory Integrity (ORI).

Organizational Structure of TGA:

The Deputy Secretary, Chief Medical Principal, Legal and Policy Advisor, First Assistant Secretary, Regulatory Practice and Vision, Medicines Regulation Division, and First Assistant Medical Devices and Product Quality Division are the executives of the Health Products Regulation Group.

1.Medicines Regulation Division:
Applications for approving novel medications for distribution in Australia are assessed by the Medicines Regulation Division. Additionally, the division is in charge of overseeing medications that have been authorized for distribution in Australia following their placement on the marketplace. Additionally, the category contains

i. Prescription Medicines Authorization:
accountable for reviewing novel medications and making a judgment on their approval or rejection.

ii. Complementary and OTC Medicines:
In charge of overseeing over-the-counter medications and complementary therapies, such as herbal and traditional remedies and vitamin and mineral supplements.

iii. Scientific Evaluation: In charge of granting approval for the marketing of biological and generic medications in Australia. Additionally, the branch offers scientific guidance to assist the Medicines Regulation Division's judgments, namely assessing the pharmaceutical chemistry and toxicological aspects of therapeutic goods and offering biological science expertise.

iv. Pharmacovigilance and Special Access Branch:
monitoring of medications and vaccines to make sure they continue to provide the right amount of efficacy, safety, and quality after being introduced to the Australian market. For all kinds of medicinal items, the division also assesses and approves specific clinical studies and special access agreements.[24]

2. Medical Devices and Product Quality Division:

The Medical Devices and Product Quality Division keeps track of medical devices that have been authorized for delivery in Australia and strives to guarantee that producers of therapeutic products, both domestically and abroad, adhere to strict guidelines. The Division consists of:

i. Medical Devices Branch:
In charge of assessing medical devices, including in vitro diagnostic tests, and keeping an eye on them over their whole lifespan to make sure they maintain the proper standards for performance, safety, and quality.

ii. Laboratories Branch:
In charge of carrying out laboratory testing, evaluating quality, and developing test procedures in scientific fields like chemistry, molecular biology, microbiology, immunobiology, biochemistry, and biomaterials engineering. A variety of medicinal goods are evaluated for market authorization by the branch, which also helps with post-market surveillance.

iii. Manufacturing Quality Branch:
In charge of granting approvals for facilities where criteria are met and making sure producers of medications, blood, tissue, and cellular treatments fulfill the necessary quality standards both domestically and internationally. Comparable foreign authorities have conducted both the physical examination of industrial facilities in stable portions.[25]

Common Technical Document (CTD):

A set of guidelines for the structure and content of a new drug application dossier was created in 2000 by members of the FDA, the European Medicines Agency, and the Japanese Ministry of Health, Labor, and Welfare. The purpose of these regulations is to ensure that all three groups abide by them. These ideas are currently included in the recommendations of the International Conference on Harmonization (ICH), a body of guidelines developed with the ICH's assistance. By developing a standard format for technical data that would enable the creation of electronic submissions, the Common Technical Document (CTD) sought to expedite the process of gathering applications for human medicine registration. Furthermore, regulatory assessments, correspondence with the applicant, and the sharing of regulatory data would all be accelerated if all regulatory bodies could utilize a single, uniform document.[26,27]

In addition to four questions and answers publications, the ICH has now released four guidelines regarding the CTD. In 2002, the first set of ICH CTD rules was published. Although CTD was created by ICH, it has also been adopted by a number of other countries, such as Canada, Australia, and India. CTD became required for NDA applications in Europe and Japan in 2003. The FDA has strongly advised CTD even though it is not currently necessary.[28] By removing the need to convert and reorganize data into other formats, CTD has already been a huge success, saving companies a ton of money and effort. Using the same format for submitting NDAs, CTD facilitates the simultaneous submission of applications in many locations. In order to streamline the process of registering new drugs in the US, EU, and Japan, the FDA defined the CTD as "a collection of data comprising scientific, manufacturing, clinical, and non-clinical information presented in a standardized format and with identical content."[29]

GUIDELINES FOR PREPARATION OF CTD:

Like all other papers, the CTD's data must be presented in an understandable and transparent manner. Tables and text should have margins that allow printing on both 8.5 × 11" (USA) and A4" (EU and Japan) paper, per the CTD organization's ICH M4 standards publication. The Times New Roman 12-point typeface is recommended for use in narrative writing. According to the Unified Criteria for Manuscript Submitted to Scientific Journals, acronyms and abbreviations must be clarified whenever they occur and each module must provide a list of references to pertinent information. All CTD publications should have page numbers beginning on page 1, with the exception of referenced works, where the current journal pagination is deemed adequate. According to the ICH M4 rules, page numbers do not always have to be shown as "1 of n," where n is the

book's overall page count. An intriguing exception from the usual is this one. For example, 2.7 Clinical Summary is an acronym for the whole subsection number and title. Each page of a publication contains a header or footer that provides a summary of its contents. Shorter numbered strings are provided by the M4 standards to prevent fifth, sixth, and so forth level subheadings (for instance, 2.6.6.3.2.1) from appearing inside a document. The document's name and document number must come first, followed by the condensed section numbers (e.g., 2.6.6 Toxicology Written Summary) at the footer or at the top of the page.[30]

ORGANIZATION OF CTD:

A broad definition of the CTD and detailed directions for document placement and pagination inside the CTD are provided in the ICH M4 guidelines 1. This degree of information is especially helpful if the dossier spans more more than one IMP indication or component. A number of questions and Answers are also provided to address the most commonly raised questions. subjects, in addition to the M4 regulations.[31] A few general rules must be followed by the applicant when completing an application. The data and information in CTD should be freely and openly provided by the applicant. The application shouldn't hide any information from regulatory agencies. "The ICH recommendations must be followed in the development of CTD." Only relevant data should be included to a CTD setup. if the applicant believes that additional material not included in the CTD must be included in order to support his application.[32,33]

Five primary modules of CTD dossier:

Module 1	Data related to administration and prescription
Module 2	Synopsis and overview of modules-3-5
Module 3	Quality (Pharmaceutical records)
Module 4	Non-clinical reports (pharmacology/toxicology
Module 5	Clinical study reports (clinical trials)

Module 1: Regional administrative information:

Module 1 is not strictly included in CTD because it is region-specific. Application forms, labeling details, and administrative data are all included.Module 1's forms and content differ between countries. [34-36]

For example, Module 1 in Europe covers clinical experts (researchers and quality assurance), but Module 1 in the US exclusively addresses financial disclosure. In the US, Module 5 provides comprehensive information on the investigator. A statement of waiving off data for in vivo experiments is required in the USA but not in Europe for Module 1. [37,38] While an environment risk certificate is required in Europe, an environment assessment statement must adhere to EPA regulations in the USA [39]. Pharmacovigilance, on the other hand, is not a component of Module 1 of the European Clinical studies Declaration (CTD), although it is incorporated into Phase IV studies and the risk management system in the United States.[40,41]

Module 2: CTD overviews and summaries:

2.1 Table of contents

2.2 Introduction

2.3 Quality overall summary

2.4 Non-clinical overview

2.5 Clinical overview

2.6 Non-clinical written and tabulated summaries

2.7 Clinical summary

Module 2.2: Introduction:

An IMP summary that covers the drug's pharmacological class, mode of action, and intended clinical usage should be included in Module 2.2. Generally speaking, the introduction should not exceed one page.[42,43]

Module 2.3: Quality overall summary:

A quality overall summary, or QOS, offers a high-level assessment of the data in the dossier with regard to chemicals, medicines, biological and biotechnological commodities, and other relevant technologies.[44] The format of the QOS is specified by the ICH M4Q standards, and the most frequently asked questions are addressed in a follow-up document. The data in the QOS generally has the same structure as the information in Module 3.[45] The QOS shouldn't contain anything that hasn't previously

been discussed in the third module or other CTD parts. Apart from talking about the key features of the product, the QOS should also address any issues that arose during development and provide justifications for any situations in which rules were broken, etc.[46,47] The QOS typically consists of 40 pages of text, omitting tables and figures; however, for biotech products and those created utilizing more complex procedures, this might be expanded to eighty pages.[48]

Module 2.4: Non-clinical overview:

The ICH M4S rules specify the structure and content of Module 2.4. The on-Clinical Overview (Module 2.4) should include a description of the data's interpretation and analysis together with an assessment of its clinical significance.[49] Furthermore, it should look at the relationship between the non-clinical outcomes and the IMP's quality components as well as the implications of these findings for the IMP's safety in human testing.[50] Any pertinent protocols that must be adhered to in order to conduct the study should be mentioned, and any inconsistencies should be clarified. Along with an evaluation of the studies' adherence to Good Laboratory Practice, a description and rationale of the non-clinical testing method should be provided. Pay particular attention to the features of comparable products and provide citations to pertinent scientific publications (for example, if a medicine classed as the IMP has been the subject of a specific discovery, it must be highlighted). The Non-Clinical Overview offers a comprehensive and critical assessment of the IMP's pharmacological, pharmacokinetic, and toxicological properties with regard to animal research. Non-clinical overviews are typically limited to thirty pages in length.[51,52]

Module 2.5: Clinical overview:

The Clinical Overview is a concise document that evaluates clinical data in a clinical trial (CTD). It consists of six parts: product development rationale, biopharmaceutics, clinical pharmacology, safety and efficacy, and product advantages and disadvantages. It provides a comprehensive overview of the medication manufacturing program and its outcomes, including relevant data like animal data and product quality issues.[53,54] The Clinical Overview does not restate previously published material; rather, it summarizes the results of a research. It emphasizes the study's applicability and backs up crucial prescription advising recommendations. A statement about research performance, clinical program quality, and adherence to Good Clinical Practice (GCP) should be included. It should discuss the IMP's place in the therapeutic toolkit if it is accepted.[55,56]

Appropriate literature references should be included in order to contextualize the findings. The advantages and drawbacks of the IMP must also be covered in the Clinical Overview, according on the findings of the clinical research that are relevant to the subject. It is crucial to assess how the safety and effectiveness findings support the recommended dose and target indication in addition to how other measures, such prescription information, would optimize benefits and reduce risks. The Clinical Overview should be around thirty pages long.[57]

Module 2.6: Non-clinical written and tabulated summaries:

The Non-Clinical Textual and Tabled Reports in Module 2.6 aim to provide comprehensive and precise non-clinical data about pharmacology, drug kinetics, and toxicity.[58-60] The average page count for non-clinical written summaries is between 100 and 150. There are 34 patterns in the ICH M4S standards that may be utilized to create tabulated summaries.[61,62]

Module 2.7: Clinical summary:

A more comprehensive document that focuses mostly on providing an overview of the facts is referred to as a "clinical summary." Giving a precise and comprehensive account of the clinical facts is the clinical summary's objective. This aggregates information from each accessible meta-analysis and other cross-study evaluations conducted, together with data on product sales in other regions.[63-65] This also includes the clinical trial reports and related data from Module 5. When comparing and evaluating the many study findings offered in this article, just make sure to stay loyal to your observations. Data interpretation is included in the Clinical Overview.[66] The Clinical Summary is composed of sections on clinical pharmacology, safety, effectiveness, biopharmaceutics, and associated analytical methods. Additionally, this module has an electronic CTD (eCTD) with the pertinent hyperlinks for each abstract of a case study report. The clinical summary is typically between 50 and 400 pages long, although it can be much longer if a significant number of indications are included.[67]

Module 3 quality:

Module 3 displays the manufacturing, chemical, and control-related parts of the product registration dossier.[68-70] The ICH M4Q regulation already contains all of the information needed for Module 3.[71-73] The pharmaceutical ingredient and drug product are covered in parts of this module. Examples of the several Module 3 components are shown below.[74-76]

3.1 Table of contents

3.2 Body of data

3.2.S Drug substance (s)

3.2.S.1 General information (name, manufacturer)

3.2.S.1.1 Nomenclature (name, manufacturer)

3.2.S.1.2 Structure (name, manufacturer)

3.2.S.1.3 General Properties (name, manufacturer)

3.2.S.2 Manufacture of drug substances (name, manufacturer)

3.2.S.2.1 Manufacturer (s) (name, manufacturer)

3.2.S.2.2 Description of manufacturing process and process control (name, manufacturer)

3.2.S.2.3 Control of materials (name, manufacturer)

3.2.S.2.4 Controls of critical steps and intermediates

3.2.S.2.5 Process validation and/or evaluation (name, manufacturer)

3.2.S.2.6 Manufacturing process development (name, manufacturer)

3.2.S.3 Characterization of drug substance

3.2.S.4 Quality control of drug substance

3.2.S.5 Reference standards or materials

3.2.S.6 Container closure system

3.2.S.7 Stability of drug substance

3.2.P Drug product (name, dosage form)

3.2.P. 1 Description and composition of the drug product

3.2.P. 2 Pharmaceutical development

3.2.P. 3 Manufacture of drug product

3.2.P. 4 Control of excipients

3.2.P. 5 Control of drug product

3.2.P. 6 Reference standards or materials

3.2.P. 7 Container closure system

3.2.P. 8 Stability of drug product

3.3 Literature reference

Module 4: Non-clinical study reports:

Module 4 covers the presentation of dossier data that is not related to clinical issues. The ICH M4S criteria are used to design the structure and content of Module 4.[77-79]

These are the main, unchanging headers of the section .[80-86]

4.1 Table of contents of Module

4 4.2 Study reports

4.2.1 Pharmacology

4.2.2 Pharmacokinetics

4.2.3 Toxicology

4.3 Literature references used in Module

Module 5: Clinical study reports:

An outline of the clinical reports that comprise the dossier is provided in Module 5. The ICH M4E guidelines dictate the structure and content of Module 5.[87-89] These recommendations provide a clear process for clinical research reports and offer additional resources to help with their submission, review, and completion.[90,91] Each report only appears in one part, which is determined by the primary objective of the study.[92] Cross-referencing across sections is necessary if the study has several objectives. The primary parts of this section that are unchangeable are as follows.[93,94]

5.1 Table of contents of Module

5 5.2 Tabular listing of all clinical studies

5.3 Clinical study report

5.3.1 Reports of biopharmaceutics studies

5.3.2 Reports of studies pertinent to pharmacokinetic using human biomaterial

5.3.3 Reports of human pharmacokinetic studies

5.3.4 Reports of human pharmacodynamic studies

5.3.5 Reports of efficacy and safety studies

5.3.6 Reports of post-marketing experience

5.3.7 Case report forms and individual patient listings

5.4 Literature references

4.3 Literature references used in Module

eCTD:

The pharmaceutical sector and regulatory bodies can communicate information through the eCTD.[95] The CTD format serves as the fundamental framework for the primary material. Its genesis was overseen by the group ICH M2 EWG, now officially known as the ICH.[96] The electronic CTD, often known as eCTD, is a conveyance format that makes it easier to transmit electronic documents and may be used as part of an organization's review procedure.[97] The eCTD will facilitate the creation, evaluation, management, and archiving of electronic submissions in addition to acting as a channel for the exchange of regulatory data between companies and governmental organizations.[98] The eCTD standards provide the conditions that must be met for an electronic submission to be regarded as technically legitimate. The amount of data available for innovative medical applications has significantly increased thanks to the eCTD. In the not-too-distant future, businesses may be able to electronically submit documents to several regulatory bodies with a single keystroke.[99]

BENEFITS OF eCTD:

1. Improved submission management and preservation benefits of eCTD
2. Better management of data
3. Assistance with life cycle management
4. Immediate access to up-to-date, thorough data
5. Improved tracking capabilities and assessor search capabilities
6. Enhanced process visibility and easier evaluation
7. Evaluation reports need less work and information reuse.
8. Restricted communication with external experts
9. More effective use of resources
10. A simpler business process
11. Better communication with business[100,101]

CONCLUSION

On the globe, the pharmaceutical business is subject to one of the strictest regulations. Regulatory Governing Bodies (Authorities) have been established globally to guarantee that pharmaceuticals designed for human use meet international criteria for efficacy, safety, and quality. For instance, the FDA, TGA, CDSCO, and so on. Regulatory affairs' job is to create and carry out regulatory strategies that guarantee the combined efforts of the drug development team will produce a product that is accepted by regulatory agencies. Drug regulatory affairs, including NDA and INDA, is a dynamic field that includes both the legal and scientific aspects of drug development. By adhering to SOPs, ICH standards, and WHO-GMP recommendations, regulatory affairs specialists help the company steer clear of issues including inaccurate scientific reasoning, badly presented data, and poorly maintained records. Since the effective acceptance of any new pharmaceutical product or molecular entity takes ten to fifteen years and requires a substantial investment of time and money, regulatory affairs is essential to all aspects of drug regulations.

REFERENCE

[1] B. Akanmori, A. Bellah, and L. Rago, ―Regulatory collaboration,‖ WHO drug Inf., vol. 29, no. 2, pp. 127– 132, 2015, [Online]. Available: http://www.who.int/medicines/publications/druginform ation/WHO_DI_29-2_RegulatoryCollaboration.pdf

[2] J. D. Green, ―Regulatory affairs introduction,‖ Toxicol. Pathol., vol. 37, no. 3, pp 361–362, 2009, doi:10.1177/0192623309332987.

[3] E. M. Cox, A. V. Edmund, E. Kratz, S. H. Lockwood, and A. Shankar, ―Regulatory Affairs 101: Introduction to Expedited Regulatory Pathways,‖ Clin. Transl. Sci., vol. 13, no. 3, pp. 451–461, 2020, doi: 10.1111/cts.12745.

[4] A. E. Mulberg et al., ―Regulatory strategies for rare diseases under current global regulatory statutes: A discussion with stakeholders,‖

Orphanet J. Rare Dis., vol. 14, no. 1, pp. 1–10, 2019, doi: 10.1186/s13023- 019-1017-5.

[5] M. Becker, K. Merz, and R. Buchkremer, ―RegTech― the application of modern information technology in regulatory affairs: areas of interest in research and practice,‖ Intell. Syst. Accounting, Financ. Manag., vol. 27, no. 4, pp. 161–167, 2020, doi: 10.1002/isaf.1479.

[6] J. Ali and S. Baboota, ―Regulatory Affairs in the Pharmaceutical Industry,‖ Regul. Aff. Pharm. Ind., vol. 2, no. 1, pp. 1–269, 2022, doi: 10.1016/C2019-0- 04686-9.

[7] O. Chisholm and H. Critchley, ―Future directions in regulatory affairs,‖ Front. Med., vol. 9, no. January, pp. 1–11, 2023, doi: 10.3389/fmed.2022.1082384.

[8] S. Kumar, R. Panwar, and U. Singh, ―Review Article Regulatory Affaurs in the Pharmacy Curriculum,‖ Int. J. Res. Dev. Pharm. Life Sci., vol. 2, no. 6, pp. 690– 698, 2013.

[9] O. Chisholm and H. Critchley, ―Future directions in regulatory affairs,‖ Front. Med., vol. 9, no. January, pp. 1–11, 2023, doi: 10.3389/fmed.2022.1082384.

[10] 10. J. K. Badjatya, ―Overview of Drug Regulatory Affairs and Regulatory Profession,‖ Int. J. Drug Regul. Aff., vol. 1, no. 1, pp. 1–4, 2013, doi: 10.22270/ijdra.v1i1.1.

[11] 11. Adams, D., Hardman, M. and Scott, A.J. (in press). Guerrilla Warfare in the Planning System: Revolution or Convergence in Spatial Planning and Sustainable Development Discourses? Geografiska Annaler B. Mahapatra AK, Sameeraja NH, Murthy PN Drug Approval Process In United States of America, European Union and India : A Review. AcrcTra, 2014; 1: 13-22.

[12] Centre for drugs Evaluation and Research hand book by Food and drug administration act.

[13] 13.Sheate, W.R. Purposes, paradigms and pressure groups: Accountability and sustainability in EU environmental assessment, 1985-2010. Environmental Impact Assessment Review,2012; 33: 91-102.

[14] Chakraborty R, Yadav K Drug approval process in US, Europe and India and its regulatory requirements: A Review, 2018; 6: 31-39.

[15] Gopinath E., Bhadauria R.S., Gunjan J., Insha Z; International Journal Of Advanced Research in Pharmaceutical & Bio Sciences, 2012; 2(2): 292-301.

[16] Uyama Y.; Successful bridging strategy based on ICH ES guideline for drugs approval in Japan. Clin. Pharmacol. Ther, 2005; 78: 102—113.

[17] Mahapatra AK, Sameeraja NH, Murthy PN Drug Approval Process In United States of America, European Union and India : A Review. AcrcTra, 2014; 1: 13-22.

[18] Rahalkar Fl.; Historical Overview of Pharmaceutical Industry and Drug Regulatory Affairs. Pharmaceutical Regulatory Affairs; 2012; 2167-7689.

[19] http://www.cdsco.nic.in/.

[20] https://www.pmda.go.jp/english/review-services/regulatory-info/0002.html

[21] https://www.regdesk.co/tga-guidance-on-patient-information-leaflets/

[22] Ilberry, B. W. Farm diversification as an adjustment strategy on the urban fringe of the West Midlands. Journal of Rural Studies, 1991; 7(3): 207-218.

[23] Frank, V. The triple bottom line and impact assessment: How do TBL, EIA, SEA and EMS relate to each other? In: Sheate, W. R. Tools, techniques and approaches for sustainability, 2004.

[24] Elson, M. Green belts - conflict and mediation in the urban fringe. Heinemann, London, 1986.

[25] Lachman L, Liberman HA, Kanig JL, The Theory and Practice of Industrial Pharmacy, Varghese Publishing House, 1987.

[26] Carl MA. Regulatory Streamlining and Improvement. Interstate Oil and Gas Compact Commission. Technical Report; 2006 Jul 11.

[27] Ahluwalia K, Abernathy MJ, Beierle J, Cauchon NS, Cronin D, Gaiki S, et al. The future of CMC regulatory submissions: Streamlining activities using structured content and data management. J Pharm Sci. 2022 May 1;111(5):1232-44.

[28] Challa SS, Chawda AD, Benke AP, Tilala M. Streamlining change control processes in regulatory affairs: Best practices and case studies. Integr J Res Arts Human. 2024 Jul 18;4(4):67-75.

[29] Alquier L, Richmond FJ. Streamlining processes-the WHO collaborative procedure for accelerated registration in Africa. Regul Rapporteur. 2021;18(9):4-7.

[30] Godiyal S. Regulatory requirements for preparation of Dossier for registration of Pharmaceutical products in ACTD & CTD

format. Int J Drug Regul Affairs. 2019;7(2):51-61.

[31] Harer SL, Aher YD, Kokane VS, Sonar PA. Comparative study of regulatory requirements for the compilation and approval of dossier; as per CTD, ACTD and ECTD formats. Int J Pharm Chem Biol Sci. 2020 Jul 1;10(3):65-74.

[32] Roth RI. Preparing the common technical document for registration of pharmaceuticals for human use (CTD)-insights and recommendations. Drug Inform J/Drug Inform Assoc. 2008 Mar;42:149-59.

[33] Fernandes DL. Critical Analysis on the Preparation of a Dossier in CTD Format for Products Developed According to the Quality-by-Design Approach (Doctoral Dissertation).

[34] World Health Organization. WHO Global Strategy for Food Safety 2022-2030: Towards Stronger Food Safety Systems and Global Cooperation. Geneva: World Health Organization; 2022 Sep 16.

[35] World Health Organization. Data Quality Review: Module 1: Framework and Metrics. Geneva: WHO; 2017.

[36] Neelima S, Govindaraj M, Subramani DK, ALkhayyat A, Mohan DC. Factors influencing data utilization and performance of health management information systems: A case study. Indian J Inform Sources Serv. 2024;14(2):146-52.

[37] Dash S, Shakyawar SK, Sharma M, Kaushik S. Big data in healthcare: Management, analysis and future prospects. J Big Data. 2019 Dec;6(1):1-25.

[38] Khan S, Yairi T. A review on the application of deep learning in system health management. Mechan Syst Signal Process. 2018 Jul 1;107:241-65.

[39] AbouZahr C, Boerma T. Health information systems: The foundations of public health. Bull World Health Organ. 2005;83:578-83.

[40] Wager KA, Lee FW, Glaser JP. Health Care Information Systems: A Practical Approach for Health Care Management. United States: John Wiley & Sons; 2021 Dec 1.

[41] Chen H, Hailey D, Wang N, Yu P. A review of data quality assessment methods for public health information systems. Int J Environ Res Public Health. 2014 May;11(5):5170-207.

[42] 3. Jordan D. An overview of the common technical document (CTD) regulatory dossier. Med Writing. 2014 Jun 1;23(2):101-5.

[43] Joubert PH, Rogers SM, Joubert PH, Rogers SM. The Common Technical Document: Overviews and Summary Documents. Strategic Scientific and Medical Writing: The Road to Success. Berlin: Springer; 2015. p. 103-11.

[44] Wimsett J, Harper A, Jones P. Components of a good quality discharge summary: Asystematic review. Emerg Med Aust. 2014 Oct;26(5):430-8.

[45] Jordan D. An overview of the Common Technical Document (CTD) regulatory dossier. Med Writing. 2014 Jun 1;23(2):101-5.

[46] Sruthi S, Srinivas N. Critical reviews of global practices of CTD and ECTD format for drug approval process.

[47] Deep A, Khurana G, Kumar J, Monga A. Comparison of regulatory requirements for registration of pharmaceutical drugs in ASEAN and GCC regions. Appl Clin Res Clin Trials Regul Affairs. 2019 Apr 1;6(1):62-70.

[48] Pritchard JF, Jurima-Romet M, Reimer ML, Mortimer E, Rolfe B, Cayen MN. Making better drugs: Decision gates in non-clinical drug development. Nat Rev Drug Discov. 2003 Jul 1;2(7):542-53.

[49] Wallis R, Benson C, Darpo B, Gintant G, Kanda Y, Prasad K, et al. CiPA challenges and opportunities from a non-clinical, clinical and regulatory perspectives. An overview of the safety pharmacology scientific discussion. J Pharmacol Toxicol Methods. 2018 Sep 1;93:15-25.

[50] Pollard CE, Abi Gerges N, Bridgland-Taylor MH, Easter A, Hammond TG, Valentin JP. An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk. Br J Pharmacol. 2010 Jan;159(1):12-21.

[51] Hajjaj FM, Salek MS, Basra MK, Finlay AY. Non-clinical influences on clinical decision-making: A major challenge to evidence-based practice. J R Soc Med. 2010 May 1;103(5):178-87.

[52] Le Floch C, Maillere P. The clinical overview and summary. In: International Pharmaceutical Product Registration. Boca Raton: CRC Press; 2016 Apr 19. p. 123-34.

[53] Molzon JA. The International Conference on harmonization common technical document-global submission format? Food Drug Law J. 2005 Jan 1;60(3):447-51.

[54] Guideline IH. The Common Technical Document for the Registration of Pharmaceuticals for Human Use Efficacy–m4e (r1) Clinical Overview and Clinical Summary of Module 2 Module 5: Clinical Study Reports; 2013. Available from: https://www.ich.org/products/ctd/ctdsingle/article/m4er1-efficacy.html [Last accessed on 2002 Sep 12].

[55] Saba V. Clinical Care Classification (CCC) System Version 2.5: User's Guide. Berlin: Springer Publishing Company; 2012 Jun 26.

[56] Guideline IH. The Common Technical Document for the Registration of Pharmaceuticals for Human Use: Safety-M4S (R2) Nonclinical Overview and Nonclinical Summaries of Module 2 Organisation of Module 4. Safety;4:R2.

[57] Badjatya JK. Overview of drug registration requirements for pharmaceuticals in emerging market. J Drug Deliv Ther. 2013 Mar 15;3(2):227-32.

[58] Nürnberg A, Pierre H. An introduction to little-known aspects of nonclinical regulatory writing. Med Writing. 2017 Dec 1;26:9-19.

[59] Marshall P. The stability dossier: Common deficiencies and ways to improve. In: Methods for Stability Testing of Pharmaceuticals. New York: Springer; 2018. p. 31-51.

[60] Metzenbauer G. Specification of a Software Package Format and Verified Installation Procedure Including Implementation for Agile and Reproducible Rollout in a Validated Pharmaceutical Sector (Doctoral Dissertation, University of Applied Sciences Technikum Wien).

[61] Van der Laan JW, Hastings KL. ICH: History and nonclinical guidances. In: Nonclinical Safety Assessment: A Guide to International Pharmaceutical Regulations. United States: Wiley; 2013 Apr 12. p. 17- 25.

[62] Fikes J, Kapeghian J, Wojcinski ZW. Overview of drug development and nonclinical safety: Role of the toxicologic pathologist and regulatory aspects. In: Toxicologic Pathology. United States: CRC Press; 2024. p. 14-37.

[63] Dudeck MA, Horan TC, Peterson KD, Allen-Bridson K, Morrell G, Pollock DA, et al. National Healthcare Safety Network (NHSN) Report, data summary for 2010, device-associated module. Am J Infect Control. 2011 Dec 1;39(10):798-816.

[64] Dudeck MA, Horan TC, Peterson KD, Allen-Bridson K, Morrell G, Anttila A, et al. National Healthcare Safety Network (NHSN) report, data summary for 2011, device-associated module. Am J Infect Control. 2013 Apr;41(4):286-300.

[65] Dudeck MA, Weiner LM, Allen-Bridson K, Malpiedi PJ, Peterson KD, Pollock DA, et al. National Healthcare Safety Network (NHSN) report, data summary for 2012, device-associated module. Am J Infect Control. 2013 Dec;41(12):1148-66.

[66] World Health Organization. WHO Consolidated Guidelines on Tuberculosis. Module 2: Screening-Systematic Screening for Tuberculosis Disease. Geneva: World Health Organization; 2021 Mar 22.

[67] Roman A. Development and validation of statistics module for quality educational research. Int J Sci Res. 2016;5(9):10-21275.

[68] Guideline IH. The Common Technical Document for the Registration of Pharmaceuticals for Human Use: Quality–M4Q (R1) Quality Overall Summary of Module 2 Module 3: Quality.

[69] Naim A, Bashir A. Application of quality matters standards on supportive and online module in higher education program. Res Revol. 2016;5(3):6-12.

[70] Shortt SE, Guillemette JM, Duncan AM, Kirby F. Defining quality criteria for online continuing medical education modules using modified nominal group technique. J Contin Educ Health Prof. 2010 Sep;30(4):246-50.

[71] Gjessing K, Torgé CJ, Hammar M, Dahlberg J, Faresjö T. Improvement of quality and safety in health care as a new interprofessional learning module-evaluation from students. J Multidiscipl Healthc. 2014 Aug 5:341-7.

[72] Huang C. Designing high-quality interactive multimedia learning modules. Comput Med Imaging Graph. 2005 Mar 1;29(2-3):223-33.

[73] Allalouf A, Gutentag T, Baumer M. Quality control for scoring tests administered in continuous mode: An NCME instructional module. Educ Measur Issues Pract. 2017 Mar;36(1):58-68.

[74] Sunde K, Eftestøl T, Askenberg C, Steen PA. Quality assessment of defibrillation and advanced life support using data from the medical control module of the defibrillator. Resuscitation. 1999 Aug 1;41(3):237-47.

[75] Mashoufi M, Ayatollahi H, Khorasani-Zavareh D. A review of data quality assessment in emergency medical services. Open Med Inform J. 2018;12:19-32.

[76] Andrade EL, Bento AF, Cavalli J, Oliveira SK, Schwanke RC, Siqueira JM, et al. Non-clinical studies in the process of new drug development-Part II: Good laboratory practice, metabolism, pharmacokinetics, safety and dose translation to clinical studies. Braz J Med Biol Res. 2016;49(12):e5646.

[77] Tavabie JA, White P. Competency-based training for the non-clinical workforce–A feasibility study, using a unique competency framework and career pathway. Educ Prim Care. 2020 May 3;31(3):169-75.

[78] Korde A, Mikolajczak R, Kolenc P, Bouziotis P, Westin H, Lauritzen M, et al. Practical considerations for navigating the regulatory landscape of non-clinical studies for clinical translation of radiopharmaceuticals. EJNMMI Radiopharm Chem. 2022 Jul 19;7(1):18.

[79] Nürnberg A, Pierre H. An introduction to little-known aspects of nonclinical regulatory writing. Med Writing. 2017 Dec 1;26:9-19.

[80] Petros N, Opacka-Juffry J, Huber JH. Psychometric and neurobiological assessment of resilience in a non-clinical sample of adults. Psychoneuroendocrinology. 2013 Oct 1;38(10):2099-108.

[81] Marin D, Drignei E. Preclinical research in human drug development. Bull Univ Agric Sci Vet Med Cluj-Napoca. 2008 Jan 1;65(1):1-5.

[82] Chitimia L, Marin D, Drignei E. Preclinical research in human drug development. Bul USAMV-CN. 2008;65:1-2.

[83] Alexander DJ, Collins CJ, Coombs DW, Gilkison IS, Hardy CJ, Healey G, et al. Association of Inhalation Toxicologists (AIT) working party recommendation for standard delivered dose calculation and expression in non-clinical aerosol inhalation toxicology studies with pharmaceuticals. Inhal Toxicol. 2008;20(13):1179-89.

[84] Guideline IH. The Common Technical Document for the Registration of Pharmaceuticals for Human use Efficacy–m4e (r1) Clinical Overview and Clinical Summary of Module 2 Module 5: Clinical Study Reports; 2013. Available from: https://www.ich.org/products/ctd/ctdsingle/article/m4er1-efficacy.html [Last accessed on 2002 Sep 12].

[85] Setia MS. Methodology series module 4: Clinical trials. Indian J Dermatol. 2016 Jul 1;61(4):393-402.

[86] Aaronson NK, Bullinger M, Ahmedzai S. A modular approach to quality-of-life assessment in cancer clinical trials. In: Cancer Clinical Trials: A Critical Appraisal. Berlin, Heidelberg: Springer; 1988 Jan 1. p. 231-49.

[87] Lassere MN, Johnson KR, Boers M, Carlton K, Day RO, De Wit M, et al. Standardized assessment of adverse events in rheumatology clinical trials: Summary of the OMERACT 7 drug safety module update. J Rheumatol. 2005 Oct 1;32(10):2037-41.

[88] Balakrishnan A, Nair S, Kunhikatta V, Rashid M, Unnikrishnan MK, Jagannatha PS, et al. Effectiveness of blended learning in pharmacy education: An experimental study using clinical research modules. PLoS One. 2021 Sep 1;16(9):e0256814.

[89] Thomas J, Bligh E, Baggus E, Thompson J. The value of a core research module in the medical curriculum. J Med Educ Res. 2021 Nov 30;1(1): 1-5.

[90] Zhao W, Pauls K. Architecture design of a generic centralized adjudication module integrated in a web-based clinical trial management system. Clin Trials. 2016 Apr;13(2):223-33.

[91] Gupta K, Arora S, Kaushal S. Modified case based learning: Our experience with a new module for pharmacology undergraduate teaching. Int J Appl Basic Med Res. 2014 Jul 1;4(2):90-4.

[92] Capili B, Baker L, Thangthaeng N, Legor K, Larkin ME, Jones CT. Development and evaluation of a clinical research nursing module for undergraduate nursing schools: Expanding Clinical Research Nurses' outreach. J Res Nurs. 2022 Mar;27(1-2):68-77.

[93] Firth JD. Medical Masterclass: Module 5-Infectious Diseases and Dermatology. England: Royal College of Physicians; 2008.

[94] Mattingly CJ, Colby GT, Forrest JN, Boyer JL. The comparative toxicogenomics database (CTD). Environ Health Perspect. 2003 May;111(6):793-5.

[95] Sama R, Latha KS, Sathish M, Krishna MG, Santhosh P. Electronic common technical document (eCTD): A review of history, benefits

of implementing, challenges, modules, risks involved in eCTD publishing and quality control. Int J Pharm Chem Biol Sci. 2016;6(2):133-49.

[96] Nakai K, Araki Y, Ebina D, Watanabe T, Tanaka Y, Toyoshima S. Electronic common technical document implementation in Japan. Drug Inform J. 2009 Jul;43(4):395-401.

[97] Cartwright AC. The electronic common technical document: From design to submission. Int J Pharm Med. 2006 Jun;20:149-58.

[98] Ross C. The History of Electronic Regulatory Submissions Technologies: A Focus on eCTD (Electronic Common Technical Document) and its Challenges and Benefits (Doctoral Dissertation, University of Georgia); 2008.

[99] Suchanek A, Ostermann H. The electronic common technical document (eCTD): An international Pro/Con analysis of the pharmaceutical product electronic submission process. Drug Inform J/Drug Inform Assoc. 2012 Jan;46(1):124-39.

[100] Sama R, Latha KS, Sathish M, Krishna MG, Santhosh P. Electronic common technical document (eCTD): A review of history, benefits of implementing, challenges, modules, risks involved in eCTD publishing and quality control. Int J Pharm Chem Biol Sci. 2016;6(2):133-49.

[101] Nakai K, Araki Y, Ebina D, Watanabe T, Tanaka Y, Toyoshima S. Electronic common technical document implementation in Japan. Drug Inform J. 2009 Jul;43(4):395-401.